Literature DB >> 3779921

Which patients benefit most from early thrombolytic therapy with intracoronary streptokinase?

F Vermeer, M L Simoons, F W Bär, J G Tijssen, R T van Domburg, P W Serruys, F W Verheugt, J C Res, C de Zwaan, A van der Laarse.   

Abstract

The effect of thrombolysis in acute myocardial infarction on enzymatic infarct size, left ventricular function, and early mortality was studied in subsets of patients in a randomized trial. Early thrombolytic therapy with intracoronary streptokinase (152 patients) or with intracoronary streptokinase preceded by intravenous streptokinase (117 patients) was compared with conventional treatment (264 patients). All 533 patients were admitted to the coronary care unit within 4 hr after onset of symptoms indicative of acute myocardial infarction. Four hundred eighty-eight patients were eligible for this detailed analysis, and 245 of these were allocated to thrombolytic therapy and 243 to conventional treatment. Early angiographic examinations were performed in 212 patients allocated to thrombolytic therapy. Patency of the infarct-related artery was achieved in 181 patients (85%). Enzymatic infarct size, as measured from cumulative alpha-hydroxybutyrate dehydrogenase release, was smaller in patients allocated to thrombolytic therapy (median 760 vs 1170 U/liter in control patients, p = .0001). Left ventricular ejection fraction measured by radionuclide angiography before discharge from the hospital was higher after thrombolytic therapy (median 50% vs 43% in control patients, p = .0001). Three month mortality was lower in patients allocated to thrombolytic therapy (6% vs 14% in the control group, p = .006). With the use of multivariate regression analysis, infarct size limitation, improvement in left ventricular ejection fraction, and three month mortality were predicted by sum of the ST segment elevation, time from onset of symptoms to admission, and Killip class at admission. Thrombolysis was most effective in patients admitted within 2 hr after onset of symptoms and in patients with a sum of ST segment elevation of 1.2 mV or more. On the other hand, no beneficial effects of streptokinase on enzymatic infarct size, left ventricular function, or mortality were observed in the subset of patients with a sum of ST segment elevation of less than 1.2 mV who were admitted between 2 and 4 hr after onset of symptoms.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3779921     DOI: 10.1161/01.cir.74.6.1379

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  14 in total

Review 1.  The electrocardiogram in ST elevation acute myocardial infarction: correlation with coronary anatomy and prognosis.

Authors:  Y Birnbaum; B J Drew
Journal:  Postgrad Med J       Date:  2003-09       Impact factor: 2.401

2.  Rescue PTCA Following Failed Thrombolysis and Primary PTCA: A Retrospective Study of Angiographic and Clinical Outcome.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1997       Impact factor: 2.300

3.  Clinical Utility of Electrocardiographic ST-Segment Area for Predicting Unsatisfactory Outcomes Following Thrombolytic Therapy.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1995       Impact factor: 2.300

4.  Prognostic significance of the distortion of terminal portion of QRS complex on admission electrocardiogram in ST segment elevation myocardial infarction.

Authors:  Dnyaneshwar V Mulay; Sachin M Mukhedkar
Journal:  Indian Heart J       Date:  2013-11-01

5.  The NVVC guidelines for the management of patients with ST-elevation acute coronary syndromes (STE-ACS).

Authors:  F W H M Bär
Journal:  Neth Heart J       Date:  2002-03       Impact factor: 2.380

6.  Enzyme tests in the evaluation of thrombolysis in acute myocardial infarction.

Authors:  C de Zwaan; G M Willems; F Vermeer; J Res; F W Verheugt; A van der Laarse; M L Simoons; J Lubsen; W T Hermens
Journal:  Br Heart J       Date:  1988-02

7.  Deciding who needs thrombolysis. Validation of ECG diagnosis inadequate.

Authors:  O M Jolobe
Journal:  BMJ       Date:  1993-09-25

8.  Saruplase is a safe and effective thrombolytic agent; observations in 1,698 patients: results of the PASS study. Practical Applications of Saruplase Study.

Authors:  F Vermeer; I Bösl; J Meyer; F Bär; B Charbonnier; J Windeler; H Barth
Journal:  J Thromb Thrombolysis       Date:  1999-08       Impact factor: 2.300

9.  Cost benefit analysis of early thrombolytic treatment with intracoronary streptokinase. Twelve month follow up report of the randomised multicentre trial conducted by the Interuniversity Cardiology Institute of The Netherlands.

Authors:  F Vermeer; M L Simoons; C de Zwaan; G A van Es; F W Verheugt; A van der Laarse; D C van Hoogenhuyze; A J Azar; F J van Dalen; J Lubsen
Journal:  Br Heart J       Date:  1988-05

Review 10.  Thrombolysis in thromboembolic diseases.

Authors:  D C Gulba; R Dechend
Journal:  Ann Hematol       Date:  1994-10       Impact factor: 3.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.